In Utah, Compound Laws tracks 19 compounds: 3 legal to sell at retail, 3 restricted, 2 in a gray area, 6 illegal, and 5 whose status varies by product form. Verified through October 22, 2026.
40761716cdc50b46**§ 58-37-4(2)(a)(iii) (hallucinogen chapeau)** — "any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of their salts, isomers, and salts of isomers … as used in this Subsection (2)(a)(iii) only, 'isomer' includes the optical, position, and geometric isomers:" — Utah Code § 58-37-4(2)(a)(iii), https://le.utah.gov/xcode/Title58/Chapter37/C58-37-S4_2022050420220504.pdf (OFFICIAL, eff. May 4, 2022). The named tryptamines/indoles are AET, Bufotenine, DET, DMT, Psilocybin, Psilocyn; 4-HO-MET is not present and no tryptamine structural class exists. **§ 58-37-2(1)(g)(i) (controlled substance analog)** — "'Controlled substance analog' means: (A) a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; (B) a substance which has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to … controlled substances listed in Schedules I and II …" — Utah Code § 58-37-2(1)(g)(i), https://le.utah.gov/xcode/Title58/Chapter37/C58-37-S2_2024031220240501.pdf (OFFICIAL, eff. Mar. 12, 2024).
e91a4daa1fef2f4f4-41-102(7)(b) "'Dosage form' does not include industrial hemp flower." 4-41-105(1) [A person may not ...] (f) "distribute, sell, or use industrial hemp flower." 4-41-105(2) "The department may seize and destroy non-compliant material." 4-41-402(1) "The sale or use of a cannabinoid product is prohibited:" [except as provided in the chapter or] "unless the United States Food and Drug Administration approves the product." [UDAF FAQ: "Smokable flower" is a prohibited product type for retail sale.] [Bracketed spans summarized; S.B. 1006 introduced text and H.B. 265 (2026) enrolled text.]
819d91abcb6742f558-37-108 Schedules of controlled substances -- Schedules I through V -- Findings required -- Specific substances included in schedules. (1) There are established five schedules of controlled substances known as Schedules I, II, III, IV, and V, which consist of substances listed in this section. (2) Schedules I, II, III, IV, and V consist of the following drugs or other substances by the official name, common or usual name, chemical name, or brand name designated: (a) Except as provided in Subsection (3), Schedule I: (i) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide); (B) Acetyl fentanyl: (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (C) Acetylmethadol; (D) Acryl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylacrylamide); (E) Allylprodine; (F) Alphacetylmethadol, except levo-alphacetylmethadol also known as levo-alpha- acetylmethadol, levomethadyl acetate, or LAAM; (G) Alphameprodine; (H) Alphamethadol; (I) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1- (1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine); (J) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4- piperidinyl]-N- phenylpropanamide); (K) Benzylpiperazine; (L) Benzethidine; (M) Betacetylmethadol; (N) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4- piperidinyl]-N- phenylpropanamide); (O) Beta-hydroxy-3-methylfentanyl, other name: N-[1-(2-hydroxy-2- phenethyl)-3-methyl-4- piperidinyl]-N-phenylpropanamide; (P) Betameprodine; (Q) Betamethadol; (R) Betaprodine; (S) Butyryl fentanyl (N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylbutyramide); (T) Clonitazene; (U) Cyclopropyl fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); (V) Dextromoramide; (W) Diampromide; (X) Diethylthiambutene; (Y) Difenoxin; Page 11 Utah Code (Z) Dimenoxadol; (AA) Dimepheptanol; (BB) Dimethylthiambutene; (CC) Dioxaphetyl butyrate; (DD) Dipipanone; (EE) Ethylmethylthiambutene; (FF) Etizolam (1-Methyl-6-o-chlorophenyl-8-ethyl-4H-s-triazolo[3,4-c]thieno[2,3-e]1,4- diazepine); (GG) Etonitazene; (HH) Etoxeridine; (II) Furanyl fentanyl (N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl] furan-2-carboxamide); (JJ) Furethidine; (KK) Hydroxypethidine; (LL) Ketobemidone; (MM) Levomoramide; (NN) Levophenacylmorphan; (OO) Methoxyacetyl fentanyl (2-Methoxy-N-(1-phenylethylpiperidinyl-4-yl)-N-acetamide); (PP) Morpheridine; (QQ) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); (RR) Noracymethadol; (SS) Norlevorphanol; (TT) Normethadone; (UU) Norpipanone; (VV) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4- piperidinyl] propanamide); (WW) Para-fluoroisobutyryl fentanyl (N-(4-Fluorophenyl)-N-(1-phenethylpiperidin-4- yl)isobutyramide); (XX) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (YY) Phenadoxone; (ZZ) Phenampromide; (AAA) Phenibut; (BBB) Phenomorphan; (CCC) Phenoperidine; (DDD) Piritramide; (EEE) Proheptazine; (FFF) Properidine; (GGG) Propiram; (HHH) Racemoramide; (III) Tetrahydrofuran fentanyl (N-(1-Phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2- carboxamide); (JJJ) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]- propanamide; (KKK) Tianeptine; (LLL) Tilidine; (MMM) Trimeperidine; (NNN) 3-methylfentanyl, including the optical and geometric isomers (N-[3-methyl-1-(2- phenylethyl)-4-piperidyl]- N-phenylpropanamide); (OOO) 3-methylthiofentanyl (N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide); Page 12 Utah Code (PPP) 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide also known as U-47700; and (QQQ) 4-cyano CUMYL-BUTINACA. (ii) Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Acetorphine; (B) Acetyldihydrocodeine; (C) Benzylmorphine; (D) Codeine methylbromide; (E) Codeine-N-Oxide; (F) Cyprenorphine; (G) Desomorphine; (H) Dihydromorphine; (I) Drotebanol; (J) Etorphine (except hydrochloride salt); (K) Heroin; (L) Hydromorphinol; (M) Methyldesorphine; (N) Methylhydromorphine; (O) Morphine methylbromide; (P) Morphine methylsulfonate; (Q) Morphine-N-Oxide; (R) Myrophine; (S) Nicocodeine; (T) Nicomorphine; (U) Normorphine; (V) Pholcodine; and (W) Thebacon. (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; as used in this Subsection (2)(a)(iii) only, "isomer" includes the optical, position, and geometric isomers: (A) Alpha-ethyltryptamine, some trade or other names: etryptamine; Monase; α-ethyl-1H- indole-3-ethanamine; 3-(2-aminobutyl) indole; α-ET; and AET; (B) 4-bromo-2,5-dimethoxy-amphetamine, some trade or other names: 4-bromo-2,5- dimethoxy-α-methylphenethylamine; 4-bromo-2,5-DMA; (C) 4-bromo-2,5-dimethoxyphenethylamine, some trade or other names: 2-(4-bromo-2,5- dimethoxyphenyl)-1-aminoethane; alpha-desmethyl DOB; 2C-B, Nexus; (D) 2,5-dimethoxyamphetamine, some trade or other names: 2,5-dimethoxy-α- methylphenethylamine; 2,5-DMA; (E) 2,5-dimethoxy-4-ethylamphetamine, some trade or other names: DOET; (F) 4-methoxyamphetamine, some trade or other names: 4-methoxy-α- methylphenethylamine; paramethoxyamphetamine, PMA; Page 13 Utah Code (G) 5-methoxy-3,4-methylenedioxyamphetamine; (H) 4-methyl-2,5-dimethoxy-amphetamine, some trade and other names: 4-methyl-2,5- dimethoxy-α-methylphenethylamine; "DOM"; and "STP"; (I) 3,4-methylenedioxy amphetamine; (J) 3,4-methylenedioxymethamphetamine (MDMA); (K) 3,4-methylenedioxy-N-ethylamphetamine, also known as N-ethyl- alpha- methyl-3,4(methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA; (L) N-hydroxy-3,4-methylenedioxyamphetamine, also known as N-hydroxy-alpha- methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA; (M) 3,4,5-trimethoxy amphetamine; (N) Bufotenine, some trade and other names: 3-(β-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N, N-dimethylserotonin; 5-hydroxy-N,N- dimethyltryptamine; mappine; (O) Diethyltryptamine, some trade and other names: N,N-Diethyltryptamine; DET; (P) Dimethyltryptamine, some trade or other names: DMT; (Q) Ibogaine, some trade and other names: 7-Ethyl-6,6β,7,8,9,10,12,13-octahydro-2- methoxy-6,9-methano-5H-pyrido [1', 2':1,2] azepino [5,4-b] indole; Tabernanthe iboga; (R) Lysergic acid diethylamide; (S) Marijuana; (T) Mescaline; (U) Parahexyl, some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9- trimethyl-6H-dibenzo[b,d]pyran; Synhexyl; (V) Peyote, meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not, the seeds thereof, any extract from any part of such plant, and every compound, manufacture, salts, derivative, mixture, or preparation of such plant, its seeds or extracts (Interprets 21 USC 812(c), Schedule I(c) (12)); (W) N-ethyl-3-piperidyl benzilate; (X) N-methyl-3-piperidyl benzilate; (Y) Psilocybin; (Z) Psilocyn; (AA) Tetrahydrocannabinols, naturally contained in a plant of the genus Cannabis (cannabis plant), except for marijuana as defined in Subsection 58-37-101(1)(w)(i)(E), as well as synthetic equivalents of the substances contained in the cannabis plant, or in the resinous extractives of Cannabis, sp. and/or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: ∆1 cis or trans tetrahydrocannabinol, and their optical isomers ∆6 cis or trans tetrahydrocannabinol, and their optical isomers ∆3,4 cis or trans tetrahydrocannabinol, and its optical isomers, and since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions covered; (BB) Ethylamine analog of phencyclidine, some trade or other names: N- ethyl-1-phenylcyclohexylamine, (1-phenylcyclohexyl)ethylamine, N-(1- phenylcyclohexyl)ethylamine, cyclohexamine, PCE; (CC) Pyrrolidine analog of phencyclidine, some trade or other names: 1-(1-phenylcyclohexyl)- pyrrolidine, PCPy, PHP; Page 14 Utah Code (DD) Thiophene analog of phencyclidine, some trade or other names: 1-[1-(2-thienyl)- cyclohexyl]-piperidine, 2-thienylanalog of phencyclidine, TPCP, TCP; and (EE) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine, some other names: TCPy. (iv) Unless specifically excepted or unless listed in another schedule, any material compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Mecloqualone; and (B) Methaqualone. (v) Any material, compound, mixture, or preparation containing any quantity of the following substances having a stimulant effect on the central nervous system, including their salts, isomers, and salts of isomers: (A) Aminorex, some other names: aminoxaphen; 2-amino-5-phenyl-2-oxazoline; or 4,5- dihydro-5-phenyl-2-oxazolamine; (B) Cathinone, some trade or other names: 2-amino-1-phenyl-1-propanone, alpha- aminopropiophenone, 2-aminopropiophenone, and norephedrone; (C) Fenethylline; (D) Methcathinone, some other names: 2-(methylamino)-propiophenone; alpha- (methylamino)propiophenone; 2-(methylamino)-1-phenylpropan-1-one; alpha-N- methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone; methylcathinone; AL-464; AL-422; AL-463 and UR1432, its salts, optical isomers, and salts of optical isomers; (E) (±)cis-4-methylaminorex ((±)cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine); (F) N-ethylamphetamine; and (G) N,N-dimethylamphetamine, also known as N,N-alpha-trimethyl-benzeneethanamine; N,N- alpha-trimethylphenethylamine. (vi) Any material, compound, mixture, or preparation that contains any quantity of the following substances, including their optical isomers, salts, and salts of isomers, subject to temporary emergency scheduling: (A) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl); and (B) N-[1- (2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl). (vii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of gamma hydroxy butyrate (gamma hydrobutyric acid), including its salts, isomers, and salts of isomers. (viii) Unless specifically excepted or unless listed in another schedule, the following substances commonly found in Mitragyna speciosa, including synthetic versions, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) 7-hydroxymitragynine (methyl (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8- methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2- enoate); and (B) Mitragynine pseudoindoxyl (methyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3- oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2- enoate). (b) Schedule II: (i) Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of Page 15 Utah Code vegetable origin, or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis: (A) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, dextrorphan, nalbuphine, nalmefene, naloxone, and naltrexone, and their respective salts, but including: (I) Raw opium; (II) Opium extracts; (III) Opium fluid; (IV) Powdered opium; (V) Granulated opium; (VI) Tincture of opium; (VII) Codeine; (VIII) Ethylmorphine; (IX) Etorphine hydrochloride; (X) Hydrocodone; (XI) Hydromorphone; (XII) Metopon; (XIII) Morphine; (XIV) Oxycodone; (XV) Oxymorphone; and (XVI) Thebaine; (B) Any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of the substances referred to in Subsection (2)(b)(i)(A), except that these substances may not include the isoquinoline alkaloids of opium; (C) Opium poppy and poppy straw; (D) Coca leaves and any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, derivative, or preparation that is chemically equivalent or identical with any of these substances, and includes cocaine and ecgonine, their salts, isomers, derivatives, and salts of isomers and derivatives, whether derived from the coca plant or synthetically produced, except the substances may not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and (E) Concentrate of poppy straw, which means the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy. (ii) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation, except dextrorphan and levopropoxyphene: (A) Alfentanil; (B) Alphaprodine; (C) Anileridine; (D) Bezitramide; (E) Bulk dextropropoxyphene (nondosage forms); (F) Carfentanil; (G) Dihydrocodeine; (H) Diphenoxylate; (I) Fentanyl; (J) Isomethadone; Page 16 Utah Code (K) Levo-alphacetylmethadol, some other names: levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM; (L) Levomethorphan; (M) Levorphanol; (N) Metazocine; (O) Methadone; (P) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane; (Q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid; (R) Pethidine (meperidine); (S) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine; (T) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate; (U) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid; (V) Phenazocine; (W) Piminodine; (X) Racemethorphan; (Y) Racemorphan; (Z) Remifentanil; and (AA) Sufentanil. (iii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system: (A) Amphetamine, its salts, optical isomers, and salts of its optical isomers; (B) Methamphetamine, its salts, isomers, and salts of its isomers; (C) Phenmetrazine and its salts; and (D) Methylphenidate. (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Amobarbital; (B) Glutethimide; (C) Pentobarbital; (D) Phencyclidine; (E) Phencyclidine immediate precursors: 1-phenylcyclohexylamine and 1- piperidinocyclohexanecarbonitrile (PCC); and (F) Secobarbital. (v) (A) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of Phenylacetone. (B) Some of these substances may be known by trade or other names: phenyl-2-propanone; P2P; benzyl methyl ketone; and methyl benzyl ketone. (vi) Nabilone, another name for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a- hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d]pyran-9-one. (vii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule II of the federal Controlled Substances Act, Title II, P.L. 91-513. Page 17 Utah Code (c) Schedule III: (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II, which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 1308.32 of Title 21 of the Code of Federal Regulations, and any other drug of the quantitive composition shown in that list for those drugs or that is the same except that it contains a lesser quantity of controlled substances; (B) Benzphetamine; (C) Chlorphentermine; (D) Clortermine; and (E) Phendimetrazine. (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the central nervous system: (A) any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital, or any salt of any of them, and one or more other active medicinal ingredients that are not listed in any schedule; (B) any suppository dosage form containing amobarbital, secobarbital, or pentobarbital, or any salt of any of these drugs that is approved by the United States Food and Drug Administration for marketing only as a suppository; (C) any substance that contains any quantity of a derivative of barbituric acid or any salt of any of them; (D) Chlorhexadol; (E) Buprenorphine; (F) any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under the federal Food, Drug, and Cosmetic Act, Section 505; (G) Ketamine, its salts, isomers, and salts of isomers, some other names for ketamine: ± -2- (2-chlorophenyl)-2-(methylamino)-cyclohexanone; (H) Lysergic acid; (I) Lysergic acid amide; (J) Methyprylon; (K) Sulfondiethylmethane; (L) Sulfonethylmethane; (M) Sulfonmethane; and (N) Tiletamine and zolazepam or any of their salts, some trade or other names for a tiletamine-zolazepam combination product: Telazol, some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone, some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e] [1,4]- diazepin-7(1H)-one, flupyrazapon. (iii) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product, some other names for dronabinol: Page 18 Utah Code (6aR-trans)-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, or (-)- delta-9-(trans)-tetrahydrocannabinol. (iv) Nalorphine. (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid: (A) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium; (B) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts; (C) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with a fourfold or greater quantity of an isoquinoline alkaloid of opium; (D) Not more than 300 milligrams of dihydrocodeinone per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; (E) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active non-narcotic ingredients in recognized therapeutic amounts; (F) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; (G) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams, or not more than 25 milligrams per dosage unit, with one or more active, non-narcotic ingredients in recognized therapeutic amounts; and (H) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams with one or more active, non-narcotic ingredients in recognized therapeutic amounts. (vi) Unless specifically excepted or unless listed in another schedule, anabolic steroids including any of the following or any isomer, ester, salt, or derivative of the following that promotes muscle growth: (A) Boldenone; (B) Chlorotestosterone (4-chlortestosterone); (C) Clostebol; (D) Dehydrochlormethyltestosterone; (E) Dihydrotestosterone (4-dihydrotestosterone); (F) Drostanolone; (G) Ethylestrenol; (H) Fluoxymesterone; (I) Formebulone (formebolone); (J) Mesterolone; (K) Methandienone; (L) Methandranone; (M) Methandriol; (N) Methandrostenolone; (O) Methenolone; (P) Methyltestosterone; (Q) Mibolerone; Page 19 Utah Code (R) Nandrolone; (S) Norethandrolone; (T) Oxandrolone; (U) Oxymesterone; (V) Oxymetholone; (W) Stanolone; (X) Stanozolol; (Y) Testolactone; (Z) Testosterone; and (AA) Trenbolone. (vii) Anabolic steroids expressly intended for administration through implants to cattle or other nonhuman species, and approved by the Secretary of Health and Human Services for use, may not be classified as a controlled substance. (viii) A drug product or preparation that contains any component of marijuana, including tetrahydrocannabinol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule III of the federal Controlled Substances Act, Title II, P.L. 91-513. (ix) Nabiximols. (d) Schedule IV: (i) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit, or any salts of any of them. (ii) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances, including its salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Alprazolam; (B) Barbital; (C) Bromazepam; (D) Butorphanol; (E) Camazepam; (F) Carisoprodol; (G) Chloral betaine; (H) Chloral hydrate; (I) Chlordiazepoxide; (J) Clobazam; (K) Clonazepam; (L) Clorazepate; (M) Clotiazepam; (N) Cloxazolam; (O) Delorazepam; (P) Diazepam; (Q) Dichloralphenazone; (R) Estazolam; (S) Ethchlorvynol; (T) Ethinamate; (U) Ethyl loflazepate; (V) Fludiazepam; Page 20 Utah Code (W) Flunitrazepam; (X) Flurazepam; (Y) Halazepam; (Z) Haloxazolam; (AA) Ketazolam; (BB) Loprazolam; (CC) Lorazepam; (DD) Lormetazepam; (EE) Mebutamate; (FF) Medazepam; (GG) Meprobamate; (HH) Methohexital; (II) Methylphenobarbital (mephobarbital); (JJ) Midazolam; (KK) Nimetazepam; (LL) Nitrazepam; (MM) Nordiazepam; (NN) Oxazepam; (OO) Oxazolam; (PP) Paraldehyde; (QQ) Pentazocine; (RR) Petrichloral; (SS) Phenobarbital; (TT) Pinazepam; (UU) Prazepam; (VV) Quazepam; (WW) Temazepam; (XX) Tetrazepam; (YY) Tramadol; (ZZ) Triazolam; (AAA) Zaleplon; and (BBB) Zolpidem. (iii) Any material, compound, mixture, or preparation of fenfluramine that contains any quantity of the following substances, including its salts, isomers whether optical, position, or geometric, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible. (iv) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers whether optical, position, or geometric isomers, and salts of the isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation: (A) Cathine ((+)-norpseudoephedrine); (B) Diethylpropion; (C) Fencamfamine; (D) Fenproprex; (E) Mazindol; (F) Mefenorex; (G) Modafinil; Page 21 Utah Code (H) Pemoline, including organometallic complexes and chelates thereof; (I) Phentermine; (J) Pipradrol; (K) Sibutramine; and (L) SPA ((-)-1-dimethylamino-1,2-diphenylethane). (v) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of dextropropoxyphene (alpha-(+)-4- dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane), including its salts. (vi) A drug product or preparation that contains any component of marijuana and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule IV of the federal Controlled Substances Act, Title II, P.L. 91-513. (e) Schedule V: (i) Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, which includes one or more non-narcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone: (A) not more than 200 milligrams of codeine per 100 milliliters or per 100 grams; (B) not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams; (C) not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams; (D) not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit; (E) not more than 100 milligrams of opium per 100 milliliters or per 100 grams; (F) not more than 0.5 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit; and (G) unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation that contains Pyrovalerone having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers. (ii) A drug product or preparation that contains any component of marijuana, including cannabidiol, and is approved by the United States Food and Drug Administration and scheduled by the Drug Enforcement Administration in Schedule V of the federal Controlled Substances Act, Title II, P.L. 91-513. (iii) Gabapentin. (3) (a) As used in this subsection, "pharmaceutical composition" means a drug that has United States Food and Drug Administration approval under 21 U.S.C. Sec. 355 following clinical trials. (b) If the federal government schedules a pharmaceutical composition of a Schedule I controlled substance or a pharmaceutical composition of any form of a Schedule I controlled substance in a schedule that is not Schedule I, that pharmaceutical composition is deemed scheduled under this section in the same schedule that the pharmaceutical composition is scheduled under 21 U.S.C. Sec. 812 and 21 C.F.R. Part 1308. Renumbered and Amended by Chapter 362, 2026 General Session
75e7b24305819d6276-9-1120. Unlawful sale of a cannabinoid inhalation product or a cannabinoid inhalation substance. (Effective 7/1/2026) (1) As used in this section: (a) "Cannabinoid inhalation product" means an electronic cigarette that contains a cannabinoid. (b) "Cannabinoid inhalation substance" means a substance containing a cannabinoid that is used or intended for use in an electronic cigarette. (c) "Compensatory service" means service or unpaid work performed by an employee, in lieu of the payment of a fine or imprisonment. (d) "Employee" means an employee or an owner of a retailer. (2) An actor commits unlawful sale of a cannabinoid inhalation product or a cannabinoid inhalation substance if the actor: (a) is an employee; and (b) intentionally or knowingly sells or gives a cannabinoid inhalation product or a cannabinoid inhalation substance in the course of business to an individual. (3) A violation of Subsection (2) is: (a) on a first violation: (i) a class C misdemeanor; and (ii) subject to: (A) a fine not exceeding $1,000; or (B) compensatory service; or (b) on a subsequent violation: (i) a class B misdemeanor; and (ii) subject to: (A) a fine not exceeding $2,000; or (B) compensatory service. (4) This section does not prohibit or restrict the sale of medical cannabis or a medical cannabis device if done in accordance with Title 26B, Chapter 4, Part 2, Cannabinoid Research and Medical Cannabis, and with Title 4, Chapter 41a, Cannabis Production Establishments and Pharmacies. Enacted by Chapter 308, 2026 General Session
4e0392801725d222(i) "Controlled substance analog" means: (A) a substance the chemical structure of which is substantially similar to the chemical structure of a controlled substance listed in Schedules I and II of Section 58-37-4, a substance listed in Section 58-37-4.2, or in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; (B) a substance that has a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513; or (C) A substance that, with respect to a particular individual, is represented or intended to have a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to the stimulant, depressant, or hallucinogenic effect on the central nervous system of controlled substances listed in Schedules I and II of Section 58-37-4, substances listed in Section 58-37-4.2, or substances listed in Schedules I and II of the federal Controlled Substances Act, Title II, P.L. 91-513. (ii) "Controlled substance analog" does not include: (A) a controlled substance currently scheduled in Schedules I through V of Section 58-37-4; (B) a substance for which there is an approved new drug application; (C) a substance with respect to which an exemption is in effect for investigational use by a particular person under Section 505 of the Food, Drug, and Cosmetic Act, 21 U.S.C. 355, to the extent the conduct with respect to the substance is permitted by the exemption; (D) any substance to the extent not intended for human consumption before an exemption takes effect with respect to the substance; (E) any drug intended for lawful use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals, which contains ephedrine, pseudoephedrine, norpseudoephedrine, or phenylpropanolamine if the drug is lawfully purchased, sold, transferred, or furnished as an over-the-counter medication without prescription; or (F) dietary supplements, vitamins, minerals, herbs, or other similar substances including concentrates or extracts, which are not otherwise regulated by law, which may contain naturally occurring amounts of chemical or substances listed in this chapter, or in rules adopted pursuant to Title 63G, Chapter 3, Utah Administrative Rulemaking Act.
74bca1343e84f1f64-41-102. Definitions. (Effective 7/1/2026) As used in this chapter: (1) "Adulterant" means any poisonous or deleterious substance in a quantity that may be injurious to human health, including: (a) pesticides; (b) heavy metals; (c) solvents; (d) microbial life; (e) artificially derived cannabinoids; (f) toxins; or (g) foreign matter. (2) (a) "Artificially derived cannabinoid" means a chemical substance that is created by a chemical reaction that changes the molecular structure of any chemical substances derived from the cannabis plant. (b) "Artificially derived cannabinoid" does not include: (i) a naturally occurring chemical substance that is separated from the cannabis plant by a chemical or mechanical extraction process; or (ii) cannabinoids that are produced by decarboxylation from a naturally occurring cannabinoid acid without the use of a chemical catalyst. (6) "Cannabinoid product" means a product that: (a) contains or is represented to contain one or more naturally occurring cannabinoids; (b) contains less than the cannabinoid product THC level, by dry weight; (c) contains a combined amount of total THC and any THC analog that does not exceed 10% of the total cannabinoid content; (d) does not exceed a total of THC and any THC analog that is greater than: (i) 5 milligrams per serving; and (ii) 150 milligrams per package; (e) unless the product is in an oil based suspension, has a serving size that: (i) is an integer; and (ii) is a discrete unit of the cannabinoid product; (f) is not an electronic cigarette as that term is defined in Section 76-9-1101; and (g) is not a cannabinoid substance that is intended for use in an electronic cigarette. (8) "Cannabinoid product THC level" means a combined concentration of total THC and any THC analog of less than 0.3% on a dry weight basis if laboratory testing confirms a result within a measurement of uncertainty that includes the combined concentration of 0.3%. (12) "Industrial hemp" means any part of a cannabis plant, whether growing or not, with a concentration of less than 0.3% tetrahydrocannabinol by dry weight. (19) "Non-compliant material" means: (a) a hemp plant that does not comply with this chapter, including a cannabis plant with a concentration of 0.3% tetrahydrocannabinol or greater by dry weight; (b) a cannabinoid product, chemical, or compound with a concentration that exceeds the cannabinoid product THC level; and (c) a cannabinoid product containing any of the following: (i) delta-9-tetrahydrocannabiphorol (THCP), the cannabinoid identified as CAS# 54763-99-4; (ii) delta-8-tetrahydrocannabiphorol (THCP), the cannabinoid identified as CAS# 51768-60-6; (iii) delta-9-tetrahyrdocannabinol (THC) acetate, the cannabinoid identified as CAS# 23132-17-4; (iv) delta-8-tetrahydrocannabinol (THC) acetate, the cannabinoid identified as CAS# 23050-54-6; (v) 9(s)-hexahydrocannabinol (HHC), the cannabinoid identified as CAS# 36403-91-5; or (vi) 9(r)-hexahyrdocannabinol (HHC), the cannabinoid identified as CAS# 36403-90-4. (23) "Tetrahydrocannabinol" or "THC" means a delta-9-tetrahydrocannabinol, the cannabinoid identified as CAS# 1972-08-3. (24) (a) "THC analog" means a substance that is structurally or pharmacologically substantially similar to, or is represented as being similar to, delta-9-THC. (b) "THC analog" does not include the following substances or the naturally occurring acid forms of the following substances: (i) cannabichromene (CBC), the cannabinoid identified as CAS# 20675-51-8; (ii) cannabicyclol (CBL), the cannabinoid identified as CAS# 21366-63-2; (iii) cannabidiol (CBD), the cannabinoid identified as CAS# 13956-29-1; (iv) cannabidivarol (CBDV), the cannabinoid identified as CAS# 24274-48-4; (v) cannabielsoin (CBE), the cannabinoid identified as CAS# 52025-76-0; (vi) cannabigerol (CBG), the cannabinoid identified as CAS# 25654-31-3; (vii) cannabigerovarin (CBGV), the cannabinoid identified as CAS# 55824-11-8; (viii) cannabinol (CBN), the cannabinoid identified as CAS# 521-35-7; (ix) cannabivarin (CBV), the cannabinoid identified as CAS# 33745-21-0; or (x) delta-9-tetrahydrocannabivarin (THCV), the cannabinoid identified as CAS# 31262-37-0. (26) "Total tetrahydrocannabinol" or "total THC" means the sum of the determined amounts of delta-9-THC, tertrahydrocannabinolic acid, calculated as "total THC = delta-9-THC + (THCA x 0.877)".
e24ce67b6aa26d9d4-41-102(18) "Non-compliant material" means: (a) a hemp plant that does not comply with this chapter, including a cannabis plant with a concentration of 0.3% tetrahydrocannabinol or greater by dry weight; (b) a cannabinoid product, chemical, or compound with a concentration that exceeds the cannabinoid product THC level; and (c) a cannabinoid product containing any of the following: (i) delta-9-tetrahydrocannabiphorol (THCP), the cannabinoid identified as CAS# 54763-99-4; (ii) delta-8-tetrahydrocannabiphorol (THCP), the cannabinoid identified as CAS# 51768-60-6; (iii) delta-9-tetrahydrocannabinol (THC) acetate, the cannabinoid identified as CAS# 23132-17-4; (iv) delta-8-tetrahydrocannabinol (THC) acetate, the cannabinoid identified as CAS# 23050-54-6; (v) 9(s)-hexahydrocannabinol (HHC), the cannabinoid identified as CAS# 36403-91-5; or (vi) 9(r)-hexahydrocannabinol (HHC), the cannabinoid identified as CAS# 36403-90-4. 4-41-105(2)(a) It is unlawful for any person to: (i) distribute, sell, or market a cannabinoid product that is: (A) not registered with the department under Section 4-41-104; or (B) non-compliant material; (ii) except as provided in Subsection (2)(b), transport into or out of the state extracted material or final product that contains 0.3% or more of total THC and any THC analog; (iii) sell or use a cannabinoid product that is: (A) added to a conventional food or beverage, as the department further defines in rules described in Section 4-41-403; (B) marketed or manufactured to be enticing to children, as further defined in rules described in Section 4-41-403; or (C) smokable flower; or (iv) knowingly or intentionally sell or give a cannabinoid product that contains THC or a THC analog in the course of business to an individual who is not at least 21 years old.
4d9b0954492abe614-41-105. Unlawful acts. (Effective 5/6/2026) (1) It is unlawful for a person to handle, process, or market living industrial hemp plants, viable hemp seeds, leaf materials, or floral materials derived from industrial hemp without the appropriate license or permit issued by the department under this chapter. (2) (a) It is unlawful for any person to: (i) distribute, sell, or market a cannabinoid product that is: (A) not registered with the department under Section 4-41-104; or (B) noncompliant material; (ii) except as provided in Subsection (2)(b), transport into or out of the state extracted material or final product that contains 0.3% or more of total THC and any THC analog; (iii) sell or use a cannabinoid product that is: (A) added to a conventional food or beverage, as the department further defines in rules described in Section 4-41-403; (B) marketed or manufactured to be enticing to children, as further defined in rules described in Section 4-41-403; or (C) smokable flower; (iv) knowingly or intentionally sell or give a cannabinoid product that contains THC or a THC analog in the course of business to an individual who is not at least 21 years old; or (v) delay or deny an inspection authorized under this chapter. (b) A person may transport transportable industrial hemp concentrate if the person: (i) complies with rules created by the department under Section 4-41-103.1 related to transportable industrial hemp concentrate; and (ii) (A) has a cannabinoid processor license; or (B) the equivalent to a cannabinoid processor license from another state. (3) The department may seize and destroy non-compliant material. (4) Nothing in this chapter authorizes any person to violate federal law, regulation, or any provision of this title.
9ea8cb56a2c6a09b(1)(a) The department shall make rules in accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act: (i) to determine standards for a registered cannabinoid product, including standards for: (A) testing to ensure the product is safe for human consumption; and (B) accurate labeling; (ii) governing an entity that manufactures cannabinoid products, including standards for health and safety; (iii) to determine when and how a cannabinoid processor's cannabinoid must be tested by the department at the expense of the cannabinoid processor; (iv) regarding what constitutes: (A) a conventional food or beverage; and (B) a product that is marketed or manufactured to be enticing to children; (v) regarding any other issue the department considers necessary for the safe production and sale of cannabinoid products; and (vi) for a cannabinoid product that is not in an oil based suspension, prohibiting a serving size that is less than the full portion of a discrete unit of the cannabinoid product. (1)(b) Notwithstanding Subsection (1)(a), the department may not prohibit a sugar coating on a cannabinoid product to mask the product's taste, subject to the limitations described in Subsection (1)(a)(iv) or (v). (2) In accordance with Title 63G, Chapter 3, Utah Administrative Rulemaking Act, the department may make rules to immediately ban or limit the presence of any substance in a cannabinoid product after receiving a recommendation to do so from a public health authority as defined in Section 26B-1-102. (3) The department shall set a fine of not more than $5,000 for a person who sells a cannabinoid product that is not registered by the department.
750702d271459fc04-45-102. Definitions. (1) "Kratom extract" means a preparation containing any part of the Mitragyna speciosa plant in a concentrated form. (2) "Kratom processor" means a person who prepares, processes, manufactures, or distributes a kratom product. (3) "Kratom product" means a product containing any part of a leaf of the plant Mitragyna speciosa. (4) "Kratom retailer" means a person who sells a kratom product for retail sale in the state. (5) "Pure leaf kratom" means a kratom product that: (a) is identifiable as plant matter or is identifiable plant matter contained in an encapsulating agent described in Subsection (5)(b); (b) is not mixed or packed with a nonkratom substance unless the nonkratom substance is an inert encapsulating agent that: (i) is composed of food-grade or pharmaceutical-grade materials with no pharmacological activity; (ii) contains no psychoactive substances, stimulants, or adulterants; and (iii) serves solely to contain or deliver the plant matter; (c) does not contain any kratom extract; and (d) does not contain 7-hydroxymitragynine at a level greater than 0.4% of the total kratom alkaloid composition of the product. (6) "Total kratom alkaloid composition" means the total amount of all alkaloids derived from the Mitragyna speciosa plant. 4-45-104. (1) A kratom processor or kratom retailer may not prepare, possess, distribute, sell, or offer for sale a kratom product that: (a) is not pure leaf kratom; and (b) does not include a product label ... that states the amount of mitragynine and 7-hydroxymitragynine ... (2) [violation] (a) class B misdemeanor for the first violation; (b) class A misdemeanor for a second violation; and (c) a third degree felony for any subsequent violation. ... (4)(c) The department may not register a person as a kratom retailer unless the kratom retailer is licensed as a retail tobacco specialty business ... 4-45-105. (1) A kratom processor or kratom retailer may not distribute, sell, or offer for sale a kratom product to an individual under 21 years old. (2) ... class A misdemeanor for each violation.
c8595ceb12be238fSec. 58-37-4(2)(a)(viii): Unless specifically excepted or unless listed in another schedule, the following substances commonly found in Mitragyna speciosa, including synthetic versions, isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, when the existence of the isomers, esters, ethers, and salts is possible within the specific chemical designation: (A) 7-hydroxymitragynine (methyl (E)-2[(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-enoate); and (B) Mitragynine pseudoindoxyl (methyl (E)-2-[(2S,6'S,7'S,8'aS)-6'-ethyl-4-methoxy-3-oxospiro[1H-indole-2,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate). Sec. 58-37-3.4. Exemption for 7-hydroxymitragynine in kratom products. (1) "pure leaf kratom" means the same as ... Section 4-45-102. (2) Notwithstanding any other provision of this chapter a person who possesses, manufactures, or distributes pure leaf kratom is not subject to the penalties described in this title for ... 7-hydroxymitragynine to the extent that ... compliance with Title 4, Chapter 45, Kratom Regulation Act. (3) ... until March 6, 2027, a person who ... in accordance with Subsection 4-45-104(5) is not subject to the penalties ... for 7-hydroxymitragynine.
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap